review
address
influenc
length
spacer
two
antibiot
molecul
biolog
activ
hybrid
structur
combin
genet
engin
techniqu
method
organ
synthesi
shown
use
design
new
potent
antifung
antibiot
base
polyen
amphotericin
b
group
mani
new
semisynthet
analogu
exhibit
import
biolog
properti
broad
spectrum
activ
low
toxic
emphasi
given
certain
aspect
relat
investig
broad
rang
biolog
activ
mechan
action
new
deriv
bibliographi
includ
refer
antibiot
commonli
use
treatment
prevent
variou
infecti
diseas
one
major
problem
modern
chemotherapi
disappoint
efficaci
use
avail
drug
resist
bacteri
strain
natur
antibiot
ie
antibiot
produc
variou
microorgan
continu
import
sourc
new
highli
activ
antimicrobi
antitumour
agent
one
relev
approach
design
new
drug
reli
target
chemic
transform
natur
antibiot
world
scienc
consider
effort
current
underway
combat
problem
resist
microorgan
avail
drug
howev
comparison
drug
develop
new
antibiot
carri
suffici
design
antiinfect
drug
creation
market
product
still
challeng
sinc
develop
medicin
treatment
chronic
diseas
much
profit
high
requir
safeti
larg
cap
pharmaceut
compani
big
pharma
shut
antibiot
research
project
current
smalland
mediums
enterpris
develop
major
new
drug
invest
ventur
capit
etc
high
demand
new
antiinfect
drug
extrem
high
cost
work
crosscountri
collabor
need
research
field
new
compound
approv
therapeut
use
human
medicin
complet
phaseiii
clinic
trial
problem
compound
fact
increas
percentag
popul
particularli
develop
countri
russia
suffer
infect
earlier
danger
ie
opportunist
infect
due
signific
decreas
immun
statu
popul
caus
natur
manmad
factor
translat
semisynthet
antitumour
antibiot
eg
doxorubicin
clinic
result
develop
gold
standard
chemotherapeut
agent
mani
antibiot
made
great
contribut
understand
mechan
develop
resist
bacteri
tumour
cell
due
high
innat
acquir
drug
resist
cancer
cell
chemotherapi
malign
tumour
often
ineffect
intern
research
commun
focus
attent
search
new
effect
less
toxic
antitumour
agent
one
ration
approach
target
therapi
base
search
inhibitor
import
tumour
cell
target
among
natur
product
primarili
antibiot
even
repurpos
known
antitumour
antibiot
consid
order
address
problem
antibiot
resist
antiinfect
agent
research
gaus
institut
new
antibiot
gina
head
academician
ussr
academi
medic
scienc
gfgaus
made
consider
contribut
discoveri
seri
origin
antibacteri
antitumour
agent
total
compound
character
introduct
medic
practic
major
achiev
institut
period
consid
review
antibiot
compris
import
class
natur
product
uniqu
structur
divers
chemic
transform
natur
antibiot
impli
chang
particular
function
group
start
molecul
preserv
structur
element
respons
biolog
activ
structur
determin
possibl
chemic
transform
antibiot
reaction
condit
exampl
mani
antibiot
contain
nitrogen
nitrogenfre
sugar
easili
elimin
acid
alkalin
media
mani
antibiot
sensit
oxid
poorli
solubl
organ
media
contrari
aqueou
solut
etc
hand
case
similar
structur
certain
moieti
eg
presenc
nh
co
h
oh
c
etc
group
method
develop
one
class
antibiot
appli
antibiot
anoth
class
goal
synthet
chemist
transform
natur
product
preserv
site
respons
biolog
activ
besid
target
modif
perform
gain
better
understand
mechan
action
particular
order
investig
interact
antibiot
target
review
follow
class
compound
consid
scaffold
synthesi
new
antibiot
polycycl
glycopeptid
vancomycin
teicoplanin
group
classic
macrolid
macrolid
amphotericin
b
oligomycin
group
anthracyclin
aureol
acid
deriv
heliomycin
synthet
benzoxaborol
antibiot
repres
eremomycin
carminomycin
olivomycin
oligomycin
heliomycin
olivomycin
modif
olivomycin
aromat
ring
aglycon
modif
olivomycin
sidechain
h
keto
group
aglycon
modif
side
chain
c
h
h
discoveri
vancomycin
teicoplanin
fig
given
impetu
research
polycycl
glycopeptid
antibiot
natur
antibiot
still
use
medic
practic
consid
reserv
antibiot
commonli
appli
treatment
infect
caus
gramposit
cocci
particularli
methicillinresist
staphylococcu
aureu
mrsa
strain
glycopeptid
antibiot
bind
high
affin
termin
daladala
group
grow
peptidoglycan
chain
outer
bacteri
cell
wall
therebi
inhibit
enzym
transpeptidas
transglycosylas
vancomycin
resist
enterococcu
strain
vre
vana
vanb
phenotyp
aris
due
replac
daladala
group
daladlact
weakli
interact
antibiot
semisynthet
glycopeptid
analogu
oritavancin
telavancin
dalbavancin
recent
use
worldwid
medicin
drug
partial
solv
problem
treatment
infecti
diseas
caus
vancomycinresist
enterococci
search
effect
glycopeptid
analogu
ongo
process
eremomycin
see
fig
natur
antibiot
group
discov
gaus
institut
new
antibiot
compound
differ
vancomycin
absenc
chlorin
atom
presenc
addit
amino
sugar
eremosamin
side
group
amino
acid
well
structur
amino
sugar
h
epivancosamin
eremosamin
dglucopyranos
moieti
attach
eremomycin
time
activ
gramposit
bacteria
antibiot
howev
drug
also
ineffect
vre
vancomycinintermedi
resist
staphylococcu
aureu
visa
recent
year
seri
new
semisynthet
deriv
eremomycin
vancomycin
teicoplanin
activ
resist
vre
visa
strain
prepar
figur
present
main
possibl
direct
modif
cand
ntermin
group
peptid
core
f
h
amino
sugar
b
amid
group
asparagin
asn
c
sugar
elimin
edman
degrad
e
antibiot
presenc
oxytripyrrolidinophosphonium
hexafluorophosph
pybop
peptid
coupl
reagent
afford
seri
new
carboxamid
deriv
eremomycin
scheme
fig
purif
compound
isol
yield
eremomycin
pyrrolidid
high
vitro
antibacteri
activ
sensit
resist
gramposit
bacteri
strain
includ
mrsa
visa
vre
isol
besid
compound
much
effect
treatment
induc
sepsi
mice
compar
vancomycin
caus
pseudoallerg
reaction
typic
mani
antibiot
group
compound
success
preclin
evalu
collabor
limit
liabil
compani
medicin
technolog
recommend
clinic
trial
eremomycin
synthes
similar
way
amid
see
scheme
vitro
assay
compound
exhibit
activ
mrsa
visa
vre
bacillu
anthraci
strain
compound
also
effect
ciprofloxacinresist
strain
bacillu
anthraci
model
vivo
assay
mice
infect
aureu
bacillu
anthraci
show
compound
provid
higher
surviv
rate
anim
compar
ciprofloxacin
pharmacolog
relev
properti
exhibit
excel
distribut
tissu
synthesi
eremomycin
carboxamid
contain
bulki
substitu
compound
presenc
pybop
ph
afford
previous
character
unsubstitut
eremomycin
amid
byproduct
compound
produc
competit
amid
reaction
antibiot
ammonia
elimin
transpeptid
asparaginecontain
peptid
alkalin
medium
origin
method
develop
select
introduct
differ
amino
acid
contain
hydrophob
substitu
glycopeptid
antibiot
via
select
aminoacyl
h
amino
group
amino
sugar
moieti
disaccharid
branch
instanc
reaction
vancomycin
nfmoc
lalanin
nhydroxysuccinimid
osu
ester
gave
figur
structur
vancomycin
teicoplanin
eremomycin
direct
chemic
modif
amid
acyl
b
alkalin
hydrolysi
c
group
follow
amid
c
sugar
elimin
edman
degrad
e
modif
ntermin
amino
group
peptid
core
f
fig
reaction
ntermin
group
peptid
core
antibiot
remain
intact
nfmoc
protect
group
easili
remov
treatment
secondari
amin
solut
compound
exhibit
high
activ
sensit
resist
clinic
strain
gramposit
bacteria
includ
vre
order
studi
detail
interact
antibiot
target
intact
bacteri
cell
solidst
nmr
spectroscopi
use
rotationalecho
doubl
reson
redor
techniqu
nh
flabel
substitu
introduc
amino
acid
residu
peptid
chain
antibiot
eremomycin
n
label
introduc
vicin
bind
pocket
antibiot
accomplish
use
carboxyeremomycin
synthes
previous
select
alkalin
hydrolysi
compound
satur
aqueou
solut
ba
oh
condit
vancomycin
decompos
carboxyeremomycin
n
bisamid
synthes
reaction
compound
appropri
amin
presenc
pybop
scheme
fig
eremomycin
synthes
convent
amid
method
presenc
pybop
redor
experi
perform
use
intact
staphylococcu
aureu
cell
grown
cultur
medium
contain
bioprecursor
isotopelabel
atom
eg
camino
acid
fcontain
antibiot
ad
medium
inhibit
bacteri
growth
form
stabl
complex
clabel
peptidoglycan
moieti
see
fig
hydrogen
bond
indic
dash
line
studi
complex
compound
provid
estim
distanc
distanc
ctermin
n
amid
eremomycin
l
c
ala
peptidoglycan
stem
see
fig
solid
arrow
consequ
higher
activ
eremomycin
amid
compar
antibiot
resist
visa
staphylococci
attribut
fact
compound
interact
peptidoglycan
via
classic
model
ie
daladala
target
also
l
c
ala
group
stem
besid
addit
bind
site
deriv
target
also
account
high
antibacteri
activ
vre
visa
previous
shown
elimin
sugar
see
fig
introduct
hydrophob
residu
aglycon
give
rise
aglycon
deriv
antibiot
exhibit
activ
differ
type
envelop
virus
modif
eremomycin
aglycon
dedmeleu
analogu
hexapeptid
produc
cleavag
amino
acid
use
edman
method
see
fig
e
teicoplanin
aglycon
gave
seri
new
hydrophob
deriv
amid
eremomycin
aglycon
hexapeptid
analogu
deriv
reaction
presenc
diphenylphosphoryl
azid
dppa
scheme
diphenylphosphoryl
azid
rather
pybop
reagent
choic
amid
aglycon
reaction
presenc
pybop
often
afford
byproduct
contain
pybop
moieti
phenol
group
aglycon
acyl
compound
ditertbutyl
dicarbon
boc
follow
amid
standard
condit
presenc
pybop
give
disubstitut
deriv
amid
nbocteicoplanin
aglycon
acyl
carbon
adoc
afford
nadocteicoplanin
aglycon
see
fig
f
scheme
compound
exhibit
high
vitro
activ
differ
coronaand
flavivirus
particular
felin
infecti
periton
viru
fipv
coronaviru
sarscov
interest
data
obtain
studi
antivir
activ
amid
eremomycin
aglycon
de
dmeleu
analogu
human
immunodefici
virus
hiv
ic
mmol
l
mmol
l
respect
compound
type
promis
select
antihiv
agent
bind
bacteri
target
appar
induc
resist
bacteria
longterm
applic
use
futur
prevent
hiv
infect
doubli
modifi
teicoplanin
deriv
nbocprotect
teicoplanin
aglycon
exhibit
high
vitro
activ
seri
flavivirus
hepat
c
viru
hcv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
dengu
viru
denv
compound
uniqu
inhibit
replic
close
relat
denv
hcv
virus
differ
mechan
former
case
inhibit
occur
stage
viru
entri
host
cell
latter
case
viru
entri
protein
kinas
play
essenti
role
viru
entri
cell
viru
replic
henc
analogu
eremomycin
teicoplanin
aglycon
includ
compound
b
b
test
panel
recombin
human
protein
kinas
pk
two
rat
liver
pk
compound
shown
inhibit
pk
activ
concentr
mmol
l
concentr
mmol
l
teicoplanin
aglycon
deriv
exhibit
higher
activ
mani
pk
compar
eremomycin
deriv
also
correl
higher
activ
mani
type
envelop
virus
kinet
analysi
inhibit
protein
kinas
demonstr
teicoplanin
nadocaglycon
compet
atp
peptid
substrat
avail
data
suggest
one
mechan
antivir
activ
glycopeptid
deriv
base
inhibit
serinethreonin
protein
kinas
synthesi
hybrid
analogu
contain
coval
bond
compound
differ
class
dualact
antibiot
differ
spectra
antibacteri
activ
promis
approach
search
new
antibacteri
agent
combat
antibiot
resist
bacteria
boron
acid
benzoxaborol
compound
capabl
interact
variou
biolog
import
compon
live
cell
alcohol
amino
alcohol
carbohydr
rna
peptid
new
class
synthet
antibiot
possess
antifung
antimicrobi
antiparasit
activ
design
synthes
base
benzoxaborol
current
develop
anacor
pharmaceut
usa
certain
start
benzoxaborol
use
synthesi
also
exhibit
biolog
activ
see
seri
hybrid
analogu
link
borol
benzoxaborol
moieti
either
directli
spacer
synthes
first
time
glycopeptid
introduc
substitu
contain
boron
acid
moieti
molecul
necessari
employ
picolin
acid
protect
group
easili
remov
weakli
acid
medium
scheme
amid
carboxyl
group
antibiot
acid
picolin
ester
presenc
pybop
gave
new
carboxamid
antibiot
hydrolysi
picolin
group
mild
condit
weakli
acid
aqueou
medium
afford
deriv
contain
unprotect
boron
acid
moieti
borolecontain
deriv
found
effect
start
antibiot
eremomycin
deriv
exhibit
highest
activ
gramposit
bacteria
effect
resist
staphylococcu
strain
visa
compar
compound
seri
vancomycin
conjug
contain
differ
type
benzoxaborol
substitu
synthes
amido
deriv
b
nacyl
deriv
nalkyl
deriv
scheme
similar
scheme
appli
synthes
benzoxaborol
deriv
eremomycin
see
scheme
teicoplanin
aglycon
scheme
carboxamid
eremomycin
see
scheme
vancomycin
see
scheme
teicoplanin
aglycon
see
scheme
synthes
standard
procedur
base
treatment
compound
respect
aminomethyl
benzo
c
ol
presenc
pybop
reaction
compound
oaminonalkylamin
afford
correspond
amid
c
n
contain
longer
spacer
reaction
osuactiv
ester
situ
gener
compound
use
synthes
n
c
propanoyl
deriv
vancomycin
teicoplanin
aglycon
alkyl
vancomycin
appropri
aldehyd
presenc
nabh
cn
afford
n
n
hdi
c
vancomycin
quantit
yield
see
scheme
amid
nacylsubstitut
teicoplanin
aglycon
appropri
amin
similar
way
synthesi
amid
gave
disubstitut
teicoplanin
aglycon
deriv
fivememb
oxaborol
ring
cleavag
observ
variou
reaction
benzoxaborol
see
scheme
presenc
peak
mz
lower
tandem
mass
spectrometri
esimsmsmrm
spectrum
compound
indic
antibiot
molecul
contain
substitu
ntermin
amino
group
peptid
core
rather
amino
sugar
n
h
group
vancosamin
fig
vancomycin
deriv
prove
less
effect
gramposit
bacteria
start
compound
except
amid
exhibit
activ
compar
vancomycin
hybrid
deriv
benzoxaborol
teicoplanin
aglycon
link
spacer
particular
length
exhibit
highest
antibacteri
activ
clinic
isol
gramposit
bacteria
c
propylamid
teicoplanin
aglycon
n
possess
particularli
high
activ
particular
vancomycinresist
strain
besid
compound
exhibit
moder
activ
vancomycinresist
enterococci
vre
minimum
inhibitori
concentr
mic
mg
ml
increas
decreas
spacer
length
introduct
two
benzoxaborol
substitu
nand
ctermin
group
peptid
found
decreas
antibacteri
activ
broadspectrum
antibacteri
drug
kanamycin
import
antibiot
aminoglycosid
aminocyclitol
class
still
use
medicin
treatment
mani
infecti
diseas
also
agricultur
aminoglycosid
activ
gramposit
gramneg
bacteria
mechan
action
relat
interact
decod
site
site
subunit
ribosom
ribonucl
acid
rrna
lead
disturb
translat
ie
protein
biosynthesi
accord
literatur
data
number
semisynthet
deriv
new
gener
synthes
base
aminoglycosid
variou
heterodimer
aminoglycosid
conjug
antibiot
report
use
medicin
synthesi
hybrid
kanamycin
conjug
glycopeptid
describ
first
time
public
kanamycin
conjug
compound
via
amino
group
antibiot
posit
acyl
amino
group
known
reduc
risk
develop
resist
prevent
deactiv
antibiot
enzym
amino
group
posit
h
amino
group
h
h
aminodglucopyranos
aminoglycosid
protect
benzyloxycarbonyl
group
cbz
h
bi
cbz
kanamycin
synthes
reaction
zinc
complex
compound
cbzcl
presenc
base
et
n
use
modifi
method
scheme
mic
mg
ml
compound
b
vre
stain
mic
mg
ml
compound
base
result
studi
method
develop
select
introduct
function
group
amino
sugar
amino
group
vancomycin
eremomycin
termin
methylamino
group
peptid
core
antibiot
remain
intact
amid
termin
carboxyl
group
antibiot
variou
amin
includ
amin
bulki
substitu
studi
detail
unusu
byproduct
amid
previous
unknown
class
antibiot
isol
optim
condit
found
amid
provid
target
product
high
yield
introduct
variou
group
glycopeptid
certain
posit
molecul
give
new
deriv
activ
bacteria
resist
initi
antibiot
glycopeptideresist
enterococci
result
discoveri
compound
exhibit
high
activ
glycopeptideresist
enterococci
mic
mg
ml
staphylococcu
aureu
intermedi
resist
glycopeptid
antibiot
mic
mg
ml
gener
eremomycin
deriv
possess
higher
vitro
antibacteri
activ
analog
vancomycin
deriv
show
signific
advantag
vancomycin
treatment
anim
mous
model
staphylococc
sepsi
condit
found
select
introduct
isotop
label
termin
carboxyl
group
asparagin
residu
peptid
core
eremomycin
carbohydr
moieti
labil
function
group
remain
intact
investig
interact
compound
nativ
cell
gramposit
bacteria
redor
techniqu
confirm
mechan
action
group
antibiot
propos
previou
studi
modif
glycopeptid
aglycon
carboxyl
amino
group
perform
seri
studi
result
discoveri
character
new
class
polycycl
peptid
exhibit
antivir
activ
micromolar
concentr
well
envelop
virus
hcv
denv
mani
correl
antivir
pk
inhibitori
activ
establish
class
hydrophob
deriv
glycopeptid
aglycon
first
heterodimer
conjug
glycopeptid
antibiot
borol
kanamycin
synthes
conjug
exhibit
activ
resist
vre
visa
strain
synthesi
chimer
heterodimer
macrolidebas
antibiot
promis
area
research
search
new
antimicrobi
agent
antibiot
among
effect
broadspectrum
antibacteri
agent
semisynthet
antibiot
clarithromycin
azithromycin
commonli
use
medicin
treatment
variou
infecti
diseas
caus
mani
gramposit
gramneg
bacteria
fig
azithromycin
best
pharmacolog
profil
among
macrolid
antibiot
mechan
action
macrolid
base
inhibit
protein
synthesi
target
macrolid
peptidyl
transferas
centr
larg
subunit
bacteri
ribosom
howev
clarithromycinand
azithromycinresist
clinic
isol
bacteria
isol
research
gaus
institut
new
antibiot
develop
method
conjug
macrolid
antibiot
benzoxaborol
polycycl
glycopeptid
antibiot
synthes
seri
new
chimer
antibiot
conjug
base
clarithromycin
azithromycin
variou
substitut
benzoxaborol
synthes
target
modif
macrolid
c
c
h
c
hh
atom
c
c
bond
see
fig
accord
literatur
data
introduct
arylalkyl
group
hh
posit
cladinos
moieti
may
help
antibiot
overcom
resist
caus
methyl
macrolidebind
site
rrna
larg
ribosom
subunit
method
develop
introduct
aminobenzoxaborol
c
hh
atom
cladinos
moieti
antibiot
carbamoyl
group
hybrid
structur
contain
hydroxam
acidderiv
benzoxaborol
c
keto
group
aglycon
prepar
modif
group
lead
loss
antibiot
activ
scheme
show
synthesi
conjug
base
clarithromycin
via
introduct
benzoxaborol
group
b
antibiot
molecul
c
atom
aglycon
c
hh
acetyl
protect
c
h
group
desosamin
former
approach
base
treatment
clarithromycin
aminoacet
acid
give
intermedi
clarithromycin
anti
ocarboxymethyl
oxim
reaction
aminobenzoxaborol
ha
figur
structur
macrolid
antibiot
clarithromycin
azithromycin
arrow
indic
direct
modif
posit
aglycon
c
h
group
desosamin
b
c
hh
atom
cladinos
c
format
c
c
cyclic
carbon
modif
c
atom
hb
give
correspond
amid
clarithromycin
ez
c
see
scheme
anoth
approach
accomplish
modifi
procedur
involv
follow
four
step
protect
c
h
group
desosamin
acetyl
group
give
h
oacclarithromycin
transform
latter
activ
h
oacclarithromycin
hh
treatment
carbonyldiimidazol
cdi
amid
amin
ha
hb
presenc
peptid
coupl
reagent
dbu
give
h
oacsubstitut
carbamoyl
deriv
clarithromycin
b
deacetyl
b
heat
methanol
form
target
unprotect
carbamoyl
deriv
clarithromycin
b
compound
c
b
exhibit
inhibitori
effect
staphylococci
streptococci
compar
activ
start
compound
assay
deriv
c
hh
cladinos
posit
found
effect
deriv
c
posit
aglycon
antibiot
compound
effect
strain
staphylococcu
epidermidi
atcc
streptococcu
pneumonia
atcc
clarithromycin
analogu
possess
opposit
activ
gramneg
bacteria
sensit
strain
e
coli
resist
strain
e
coli
tolc
tolc
puc
thu
compound
activ
former
case
e
coli
tolc
tolc
puc
bacteri
strain
contain
outer
membran
protein
tolc
respons
antibiot
efflux
cell
latter
case
strain
contain
apart
tolc
puc
plasmid
clone
vector
methylas
attempt
made
extend
method
develop
synthesi
c
hh
substitut
clarithromycin
benzoxaborol
conjug
synthesi
relat
azithromycin
conjug
scheme
appear
success
introduc
aminobenzoxaborol
moieti
macrolid
antibiot
depend
structur
antibiot
well
structur
aminobenzoxaborol
acetyl
azithromycin
give
h
oac
deriv
follow
treatment
latter
n
n
h
carbonyldiimidazol
presenc
et
n
produc
desir
activ
imidazol
deriv
azithromycin
h
hh
see
scheme
howev
unlik
synthesi
clarithromycin
analogu
amid
compound
c
oxaborol
methylamin
presenc
dbu
give
desir
outcom
introduct
latter
amin
accomplish
use
trisubstitut
deriv
carbon
azithromycin
h
hh
substrat
compound
condit
use
success
see
scheme
meanwhil
reaction
anoth
amin
contain
aminoethyl
spacer
give
correspond
azithromycin
carbamoyl
deriv
see
scheme
howev
elimin
h
oac
group
final
result
decomposit
deacetyl
deriv
purif
silica
gel
altern
procedur
introduct
benzoxaborol
molecul
use
carboxi
deriv
diaminoalkan
spacer
scheme
prove
success
treatment
imidazol
deriv
stronger
base
diaminoethan
presenc
dbu
result
format
aminoalkylcarbamoyl
deriv
n
n
subsequ
acyl
latter
variou
benzoxaborol
acid
standard
condit
dcc
hobt
give
seri
acylaminoalkylbenzoxaborolecontain
carbamoyl
deriv
carbon
h
oacazithromycin
see
scheme
deacetyl
compound
afford
correspond
cyclic
carbon
contain
free
c
h
group
desosamin
moieti
r
h
quantit
yield
compound
h
oac
analogu
synthes
azithromycin
h
hh
intermedi
h
oac
analogu
n
scheme
therefor
synthesi
compound
h
oac
analogu
show
introduct
acylaminoalkylbenzoxaborol
moieti
accomplish
use
scheme
describ
without
protect
c
c
group
cyclic
carbon
evalu
antibacteri
activ
hh
osubstitut
deriv
n
n
n
compar
compound
show
activ
compound
gramneg
bacteria
isol
lower
gramposit
bacteria
isol
exampl
activ
compound
n
n
n
gramposit
strain
streptococcu
pyogen
atcc
propionibacterium
acn
atcc
compar
start
com
pound
conjug
n
n
n
n
effect
compound
strain
streptococcu
pneumonia
atcc
enterococcu
faecium
presenc
h
oac
group
carbon
analog
hybrid
antibiot
found
almost
effect
antibacteri
activ
compound
n
n
n
n
n
mechan
antibacteri
activ
studi
use
report
construct
respond
inhibitor
transloc
ribosom
along
matrix
nucleic
acid
mrna
compound
found
inhibit
peptid
chain
growth
exit
ribosom
tunnel
like
typic
macrolid
antibiot
worth
note
one
start
benzoxaborol
acid
c
propano
acid
see
scheme
mark
asterisk
also
exhibit
activ
assay
azithromycin
benzoxaborol
conjug
group
aglycon
carbon
use
protect
group
two
hydroxyl
group
also
activ
group
introduc
benzoxaborol
substitu
posit
antibiot
reaction
carbon
azithromycin
h
oac
deriv
gener
azithromycin
two
step
treatment
ethylen
carbon
follow
acyl
h
group
desosamin
moieti
diaminoalkan
gave
h
oacetylazithromycin
n
scheme
acyl
compound
benzoxaborol
acid
standard
condit
dcc
hobt
produc
seri
azithromycin
h
oac
deriv
deacetyl
compound
afford
target
benzoxaborol
deriv
new
hybrid
antibiot
exhibit
broaderspectrum
antibacteri
activ
gramposit
gramneg
bacteria
compar
azithromycin
tobramycin
compound
prove
effect
compound
seri
activ
lower
compound
modifi
antibiot
overcom
antibiot
resist
mrsa
strain
strain
atcc
higher
activ
three
compound
sensit
strain
pneumonia
atcc
compar
tobramycin
mic
versu
mg
ml
particularli
valuabl
properti
dcc
hobt
dcc
n
n
h
dicyclohexyl
carbodiimid
hobt
former
case
reaction
azithromycin
n
antibiot
presenc
pybop
afford
correspond
deriv
vancomycin
eremomycin
teicoplanin
aglycon
scheme
latter
case
carbon
azithromycin
hh
oalkylaminocarbamoyl
deriv
amid
antibiot
presenc
pybop
scheme
remov
h
oacetyl
protect
group
compound
column
chromatograph
separ
silan
silica
gel
follow
sephadex
chromatographi
five
new
conjug
isol
yield
base
correspond
start
antibiot
antibacteri
activ
deriv
modifi
c
group
aglycon
evalu
compar
start
antibiot
vancomycin
azithromycin
panel
gramposit
gramneg
bacteri
strain
strain
respect
none
conjug
exhibit
activ
gramneg
bacteria
attest
absenc
effect
azithromycin
moieti
activ
gramneg
bacteria
gener
compound
display
similar
somewhat
lower
activ
gramposit
bacteri
strain
compar
compound
activ
staphylococci
higher
streptococci
pneumonia
atcc
agalacti
azithromycin
teicoplanin
aglycon
conjug
contain
long
spacer
n
exhibit
higher
activ
test
gramposit
bacteri
strain
staphylococci
deriv
hh
cladinos
posit
show
similar
tendenc
thu
inact
gramneg
bacteria
fact
hybrid
structur
ineffect
e
coli
atcc
gramneg
bacteri
strain
indic
penetr
outer
phospholipid
layer
bacteri
cell
test
gramposit
bacteri
strain
compound
exhibit
activ
compar
higher
azithromycin
vancomycin
activ
provid
presenc
glycopeptid
moieti
unlik
hybrid
vancomycin
analogu
hybrid
eremomycin
analogu
display
signific
activ
vancomycinresist
enterococci
vre
strain
enterococcu
faecium
enterococcu
faecali
mic
mmol
l
attribut
effect
azithromycin
moieti
attach
ctermin
group
peptid
core
antibiot
mechan
action
gramposit
bacteria
confirm
quantum
chemic
calcul
energi
interact
dg
relat
hybrid
antibiot
model
daladala
ligand
typic
glycopeptid
studi
result
develop
method
synthesi
macrolidebas
hybrid
antibiot
contain
benzoxaborol
new
pharmacophor
behaviour
macrolid
antibiot
aglycon
chemic
reaction
found
affect
structur
particular
depend
presenc
addit
methylamino
group
azithromycin
posit
benzoxaborol
substitu
shown
influenc
antibacteri
activ
antibiot
establish
c
substitut
analogu
less
effect
inhibitor
gramposit
gramneg
bacteria
compar
hh
substitut
analogu
presenc
carbon
h
oacetyl
group
azithromycin
molecul
shown
signific
effect
antibacteri
activ
conjug
increas
spacer
length
gener
lead
increas
activ
final
compound
method
develop
synthesi
seri
chimer
antibiot
base
glycopeptid
azithromycin
activ
almost
synthes
compound
test
gramposit
bacteri
strain
includ
vancomycinresist
strain
similar
higher
start
antibiot
rang
antibacteri
activ
result
hybrid
deriv
quantum
chemic
calcul
suggest
antibacteri
activ
determin
presenc
glycopep
carbohydratecontain
polyen
macrolid
commonli
use
medicin
treatment
superfici
system
mycos
due
high
activ
broad
spectrum
action
mechan
action
polyen
macrolid
relat
abil
interact
sterolcontain
cytoplasm
membran
form
pore
channel
membaran
ion
leav
cell
caus
death
efficaci
polyen
fungal
pathogen
due
stronger
bind
fungal
membran
ergosterol
compar
cholesterol
present
human
anim
cell
membran
nystatin
partricin
pimaricin
administ
local
wherea
amphotericin
b
amb
polyen
appli
treatment
system
mycos
unfortun
polyen
rather
toxic
agent
low
select
fungal
versu
mammalian
cell
poor
solubl
polyen
water
high
hematotox
nephrotox
number
advers
effect
stimul
extens
search
new
less
toxic
effect
agent
previous
shown
toxic
compound
polyen
reduc
chemic
modif
lead
decreas
side
effect
toxic
effect
compound
blood
cell
haemolysi
particularli
danger
order
improv
antifung
properti
cytotox
therapeut
characterist
studi
mechan
action
seri
new
semisynthet
deriv
base
amb
bioengin
analogu
synthes
collabor
compani
biosergen
norway
scheme
structur
divers
abovement
polyen
provid
use
method
genet
engin
alter
gene
encod
nystatinproduc
strain
streptomyc
noursei
new
analogu
compar
favour
nystatin
primarili
due
presenc
doubl
bond
instead
singl
one
c
c
characterist
polyen
heptaen
group
aglycon
impart
rigid
antibiot
structur
improv
antifung
activ
new
monosubstitut
polyen
macrolid
termin
h
group
aglycon
synthes
base
compound
monosubstitut
polyen
macrolid
mycosamin
h
amino
group
prepar
base
synthesi
doubli
modifi
analogu
antibiot
report
relat
amido
deriv
substitut
similar
way
c
carboxamid
group
prepar
yield
c
amido
deriv
depend
structur
start
amin
antibiot
antibiot
structur
found
almost
effect
antifung
activ
fungal
strain
candida
albican
atcc
cryptococcu
humicolu
atcc
aspergillu
niger
atcc
fusarium
oxysporum
vkm
activ
pair
deriv
contain
substitu
almost
magnitud
carboxamid
g
e
found
effect
abovement
strain
mic
mg
ml
major
direct
chemic
modif
mycosamin
h
amino
group
alkyl
aminoacyl
reaction
aminocontain
reagent
protect
fmoc
group
convent
h
nalkyl
deriv
polyen
h
n
substitut
compound
n
ndi
aminopropyl
substitut
compound
synthes
reduct
alkyl
compound
appropri
aldehyd
presenc
nacnbh
see
scheme
condit
b
c
yield
compound
respect
start
antibiot
h
nacyl
deriv
synthes
reaction
antibiot
n
n
e
fmoc
llysin
presenc
pybop
yield
see
scheme
condit
remov
fmoc
group
intermedi
deriv
p
g
piperidin
solut
dmso
afford
correspond
h
naminoacyl
deriv
n
e
yield
evalu
influenc
substitu
termin
group
c
atom
aglycon
mycosamin
amino
group
antifung
activ
polyen
show
replac
co
h
group
signific
effect
antifung
activ
test
strain
activ
analogu
similar
analogu
thu
effect
modif
activ
initi
antibiot
close
valu
antifung
activ
multidirect
mic
valu
chang
follow
seri
remov
fmoc
protect
group
compound
gave
h
n
llysyl
n
amid
altern
scheme
involv
initi
synthesi
fmocprotect
h
naminoacyl
deriv
follow
transform
correspond
c
carboxamid
scheme
reaction
compound
acid
presenc
pybop
afford
h
n
amid
latter
appropri
amin
presenc
pybop
give
h
n
dmaeamid
known
compound
prepar
reaction
n
n
e
fmoc
lli
presenc
dcc
hobt
use
synthes
n
amid
n
n
e
fmoc
remov
fmoc
group
compound
mild
condit
gave
target
product
contain
free
amino
group
see
scheme
evalu
antifung
activ
doubli
modifi
deriv
abovement
four
fungal
strain
compar
correspond
monomodifi
c
carboxamid
c
demonstr
addit
modif
mycosamin
h
amino
group
carboxamid
signific
effect
antifung
activ
fungal
yeast
strain
mic
mg
ml
meanwhil
correspond
modif
lead
consider
decreas
antifung
activ
seri
doubli
modifi
deriv
ndimethylethylamid
respect
prepar
via
amadori
rearrang
dglucos
dgalactos
exhibit
highest
activ
similar
start
antibiot
experi
anim
play
signific
role
select
lead
antifung
agent
sinc
rather
toxic
amb
use
treatment
system
fungal
infect
compound
exhibit
highest
vitro
activ
current
test
haemolysi
acut
toxic
new
genet
engin
polyen
macrolid
semisynthet
deriv
h
doubli
modifi
h
n
dmae
evalu
antifung
activ
treatment
candida
albicansinduc
sepsi
mice
test
toxic
largest
margin
therapeut
toxic
dose
observ
compound
compound
effect
dose
maximum
toler
dose
mtd
respect
wherea
amb
effect
dose
mtd
antifung
activ
c
methylc
decarboxypolyen
four
fungal
strain
chang
follow
order
c
c
c
c
c
confirm
pattern
chang
activ
c
albican
observ
previous
seri
c
carboxycontain
antibiot
similar
arrang
hydroxyl
group
c
c
c
c
follow
amid
synthes
polyen
n
ndimethylamino
ethylamin
accord
convent
amid
method
presenc
pybop
see
scheme
activ
compound
like
start
antibiot
chang
similar
seri
worth
note
low
antifung
activ
compound
confirm
also
anim
experi
relat
treatment
murin
candida
sepsi
studi
clearli
demonstr
c
group
polyol
moieti
play
critic
role
antifung
activ
although
group
previous
consid
import
model
antibiot
bind
target
compound
contain
singl
hydroxyl
group
posit
c
exhibit
low
activ
test
fungal
strain
polyen
contain
two
hydroxyl
group
posit
inact
antibiot
semisynthet
deriv
contain
hydroxyl
group
posit
amb
b
c
c
atom
b
b
display
best
result
design
hybrid
analogu
antibiot
contain
pharmacophor
moieti
affect
target
differ
use
start
antibiot
promis
line
research
benzoxaborolecontain
compound
exhibit
pronounc
antifung
activ
method
develop
synthesi
dualact
antibiot
base
amb
differ
type
benzoxaborol
follow
five
type
conjug
synthes
depend
natur
function
group
benzoxaborol
use
attach
latter
amb
molecul
c
h
nsulfo
deriv
h
nmonoand
h
n
ndialkyl
deriv
scheme
amid
produc
standard
procedur
appli
prepar
abovedescrib
amid
howev
yield
low
appar
amid
interfer
format
aminoborol
complex
amb
mention
yield
amb
carboxamid
reaction
use
amin
higher
h
nderiv
prepar
amb
use
situ
gener
osuactiv
ester
h
nsulfo
deriv
synthes
reaction
appropri
sulfochlorid
presenc
pyridin
py
h
nalkyl
analogu
prepar
reaction
appropri
aldehyd
presenc
nabh
cn
amid
deriv
n
ndimethylethylenediamin
presenc
pybop
gave
respect
scheme
attempt
synthes
disubstitut
h
nalkyldma
analogu
accord
similar
scheme
h
nalkylamino
deriv
fail
see
scheme
nevertheless
compound
prepar
use
altern
approach
alkyl
c
amid
deriv
c
presenc
nabh
cn
see
scheme
tandem
mass
spectrometri
esimsmsmrm
studi
show
differ
fragment
pattern
possibl
depend
modif
start
polyen
scheme
mani
case
introduct
benzoxaborol
substitu
lead
decreas
cytotox
haemolyt
activ
retent
high
antifung
activ
fact
confirm
membran
activ
assay
result
given
tabl
semisynthet
amb
deriv
e
b
b
shown
signific
poreform
abil
artifici
form
sterolcontain
membran
compound
high
antifung
activ
low
haemolysi
higher
select
ergosterolcontain
fungal
membran
c
chol
c
erg
versu
cholesterolcontain
human
cell
membran
compar
compound
exampl
high
select
ae
compound
correl
low
haemolysi
human
erythrocyt
contrari
high
haemolysi
determin
low
even
revers
select
c
chol
c
erg
ae
amb
deriv
correspond
paramet
intermedi
valu
c
chol
c
erg
haemolysi
amphotericin
b
select
modifi
mycosamin
h
amino
group
c
carboxyl
group
develop
approach
extend
relat
polyen
genet
engin
polyen
differ
start
amb
substitu
c
atom
posit
hydroxyl
group
c
c
aglycon
moieti
structur
activ
relationship
analysi
new
semisynthet
deriv
polyen
macrocycl
reveal
sever
gener
featur
antifung
activ
particular
antibiot
consequ
semisynthet
analogu
contain
two
hydroxyl
group
region
posit
amb
posit
exhibit
high
activ
seri
new
semisynthet
deriv
shown
poreform
abil
artifici
form
sterolcontain
membran
worth
note
select
activ
ergosterolcontain
fungal
membran
lower
haemolysi
compar
amphotericin
b
aim
chemic
modif
antibiot
oligomycin
fig
act
f
f
atp
synthas
inhibitor
prepar
new
analogu
possess
select
antitumour
antiinfect
activ
elucid
mechan
sensit
microorgan
agent
oligomycin
hereinaft
oligomycin
belong
macrolid
bunsubstitut
macrolacton
highli
specif
inhibitor
oxid
phosphoryl
mitochondria
eukaryot
oligomycin
inhibit
adenosin
triphosph
atp
synthesi
caus
cell
death
note
cerg
minimum
concentr
compound
caus
pore
format
dphpcerg
bilay
ccholcerg
ratio
minimum
concentr
polyen
dphpcchol
dphpcerg
bilay
dphpc
chol
cholesterol
erg
ergosterol
oligomycin
molecul
found
contain
function
group
chemic
modif
produc
largest
number
semisynthet
analogu
variou
biolog
activ
dock
studi
interact
antibiot
target
enzym
f
f
atp
synthas
show
c
side
chain
directli
involv
format
complex
seri
oligomycin
deriv
synthes
use
oligomycin
key
compound
prepar
select
treatment
methanesulfonyl
chlorid
dmap
py
mixtur
scheme
nucleophil
substitut
group
r
via
n
n
mechan
use
variou
reagent
gave
follow
deriv
oligomycin
thiocyanooligomycin
r
bromooligomycin
azidooligomycin
see
scheme
racem
observ
deriv
antibiot
oligomycin
synthes
solvolysi
r
deoxyomesyl
oligomycin
aqueou
mixtur
tiourea
methyl
cellosolv
heat
reaction
involv
walden
invers
configur
c
atom
plausibl
mechan
present
scheme
biolog
activ
assay
compound
reveal
invers
hydroxyl
group
decreas
activ
actinobacteria
streptomyc
fradia
antifung
activ
remain
level
oligomycin
exhibit
somewhat
higher
activ
tumour
cell
compar
start
analogu
antibiot
abl
overcom
differ
drug
resist
phenotyp
low
toxic
nonmalign
cell
treatment
oligomycin
formic
acid
afford
c
oformyloligomycin
see
scheme
formyl
deriv
retain
abil
inhibit
tumour
cell
growth
wherea
activ
test
cultur
includ
nonmalign
cell
decreas
due
select
tumour
cell
c
oformyloligomycin
hold
promis
investig
oligomycin
quantit
convert
kornblum
oxid
dmso
et
n
mixtur
see
scheme
attempt
oxid
oh
group
c
atom
oligomycin
keto
group
use
differ
oxid
agent
fail
cite
studi
interest
structur
previous
present
new
natur
compound
howev
structur
compound
describ
detail
biolog
activ
evalu
deriv
exhibit
twice
lower
activ
fradia
compar
com
pound
activ
candida
spp
filament
fungi
similar
compound
dock
studi
bind
deriv
f
f
atp
synthas
also
show
affin
enzym
decreas
compar
start
antibiot
method
synthesi
oligomycin
develop
base
method
involv
regioselect
dipolar
cycloaddit
group
monosubstitut
alkyn
scheme
reaction
azid
alkyn
phenylacetylen
propiol
acid
methyl
propiol
tertbutanol
water
mixtur
perform
presenc
catalyst
cu
without
catalyst
approach
appli
synthes
oligomycin
oligomycin
oligomycin
yield
respect
compound
serv
start
compound
synthesi
watersolubl
oligomycin
amid
exhibit
select
antitumour
activ
oligomycin
undergo
retroaldol
rearrang
accompani
dehydr
presenc
base
scheme
structur
alkalin
degrad
product
establish
detail
h
c
nmr
studi
includ
heteronuclear
correl
combin
tandem
mass
spectrometri
esimsmsmrm
structur
carbon
skeleton
start
antibiot
undergo
signific
transform
c
cleavag
pathway
b
c
give
openr
compound
mechan
alkalin
degrad
oligomycin
present
scheme
account
format
deriv
intermedi
format
intermedi
f
oppos
compound
compound
exhibit
activ
proteasom
f
f
atp
synthas
concentr
mmol
l
loss
conform
rigid
hydrogen
oligomycin
palladium
catalyst
occur
bond
lacton
dien
system
c
hydrogen
compound
condit
lead
sequenti
select
reduct
keto
group
first
c
atom
c
atom
thu
use
nabh
oac
latter
nabh
ethanol
afford
tetrahydrooligomycin
see
scheme
hydrogen
doubl
bond
macrolacton
ring
caus
decreas
activ
compound
actinobacteria
fungal
mammalian
cell
may
attribut
loss
conform
rigid
fact
geometri
macrocycl
favour
interact
target
f
f
atp
synthas
chang
destruct
dien
system
start
antibiot
retent
activ
start
compound
strain
candida
spp
support
previou
suggest
addit
target
yeast
cell
genu
bind
appar
independ
geometri
macrocycl
reaction
compound
mchloroperoxybenzo
acid
mcpba
dichloromethan
decreas
reaction
temperatur
allow
select
epoxid
oligomycin
one
c
c
bond
form
unstabl
intermedi
epoxid
scheme
presenc
formic
acid
latter
compound
give
stabl
disubstitut
oligomycin
deriv
previous
deriv
antibiot
synthes
use
nbromosuccinimid
bromin
agent
see
scheme
addit
hydroxylamin
relat
compound
studi
comprehens
studi
result
compound
h
c
nmr
spectroscopi
includ
heteronuclear
correl
made
possibl
establish
structur
nitron
exclud
possibl
exist
isom
found
addit
ring
involv
c
c
atom
form
activ
antibiot
f
f
atp
synthas
reduc
reaction
antibiot
aminopyridinium
iodid
pyridin
afford
cyclic
deriv
pyrazolo
pyridin
pyridin
b
respect
annul
macrocycl
see
scheme
structur
establish
h
c
nmr
spectroscopi
includ
heteronuclear
correl
structur
exclud
biolog
assay
new
deriv
oligomycin
demonstr
case
modif
reduc
biolog
activ
start
antibiot
fradia
growth
inhibit
assay
strain
fradia
atcc
sensit
low
concentr
oligomycin
nmol
ml
nmol
per
disc
surfac
hypersensit
known
antibiot
use
studi
mechan
resist
microorgan
mutant
strain
microorgan
sensit
analogu
compound
ref
oppos
start
antibiot
deriv
produc
experiment
condit
result
assay
demonstr
antibiot
sever
biotarget
data
confirm
conclus
dien
system
macrocycl
hydroxypropyl
side
chain
play
import
role
biolog
activ
therefor
chemic
modif
antibiot
oligomycin
highli
activ
f
f
atp
synthas
inhibitor
perform
first
time
new
semisynthet
oligomycin
deriv
prepar
mechan
action
studi
analogu
select
antitumour
antiinfect
activ
synthes
chemic
modif
antibiot
enabl
effici
modul
biolog
activ
due
decreas
bind
f
f
atp
synthas
found
provid
possibl
optim
pharmacolog
properti
olivomycin
hereinaft
olivomycin
highli
effect
antibiot
uniqu
mechan
antitumour
activ
discov
gaus
institut
new
antibiot
fig
structur
consist
aglycon
olivin
two
carbohydr
chain
attach
aglycon
posit
antibiot
dna
duplex
minor
groov
ligand
bind
guaninecytosin
gc
rich
region
compar
antibiot
aureol
acid
group
mithramycin
chromomycin
olivomycin
better
therapeut
efficaci
recent
year
antibiot
group
attract
increas
interest
antibiot
group
shown
abl
prevent
develop
resist
tumour
cell
antitumour
agent
particular
via
mechan
involv
inhibit
transcript
gene
overexpress
respons
multidrug
resist
tumour
cell
mithramycin
use
treat
paget
diseas
testicular
carcinoma
chromomycin
drug
limit
use
japan
treatment
gastrointestin
cancer
olivomycin
appli
ussr
treatment
ovarian
cancer
reticulosarcoma
tumour
howev
seriou
advers
effect
limit
therapeut
potenti
drug
variou
aspect
antitumour
activ
antibiot
aureol
acid
group
address
detail
howev
chemic
modif
class
antibiot
poorli
known
select
modif
olivomycin
c
atom
c
b
c
h
group
c
c
h
h
bond
residu
e
see
fig
develop
gaus
institut
new
antibiot
select
acyl
compound
phenol
hydroxyl
group
c
atom
ac
mixtur
afford
scheme
investig
reaction
olivomycin
aryldiazonium
salt
show
azo
coupl
give
aryldiazen
monosubstitut
posit
aglycon
accompani
elimin
disaccharid
branch
c
atom
phenyldiazenyl
olivomycin
olivomycin
olivomycin
olivomycin
olivomycin
see
scheme
explain
outcom
reaction
frontier
electron
densiti
highest
occupi
molecular
orbit
homo
calcul
semiempir
quantum
chemic
method
fukui
indic
f
altern
direct
nucleophil
attack
phenyldiazonium
cation
chosen
consid
possibl
anion
form
olivomycin
scheme
found
posit
anion
favour
electrophil
attack
give
compound
fukui
index
f
homo
meanwhil
nucleophil
c
c
atom
lower
respect
format
anion
alkalin
medium
confirm
abovement
select
acyl
compound
give
acet
hydroxyl
group
c
atom
high
yield
see
scheme
calcul
energi
paramet
alkalin
hydrolysi
disaccharid
branch
agreement
experiment
data
thu
hydrolysi
proce
rapidli
presenc
diazenyl
substitu
posit
storag
alkalin
medium
use
azo
coupl
cool
h
absenc
diazonium
salt
lead
hydrolysi
azo
coupl
aryldiazonium
salt
aglycon
olivomycin
olivin
synthes
quantit
acid
hydrolysi
compound
investig
aryldiazenyl
deriv
olivin
c
contain
substitu
compound
scheme
synthes
geometr
configur
probabl
tautomer
structur
deriv
determin
scheme
total
energi
tautomer
form
calcul
densiti
function
theori
level
theori
h
nmr
spectroscop
data
also
indic
compound
c
exist
equilibrium
mixtur
isomer
form
reaction
olivomycin
ocarboxymethyl
hydroxylamin
afford
h
carboxymethoxim
olivomycin
cm
scheme
introduct
carboxyl
group
molecul
make
possibl
subject
compound
modif
reaction
compound
appro
introduct
carboxyl
group
molecul
case
long
acid
provid
rout
modif
reaction
short
osa
appropri
amin
presenc
pybop
diphenylphosphoryl
azid
dppa
afford
osa
nmethylamid
worth
note
method
develop
synthesi
intermedi
osa
appli
prepar
relat
deriv
mithramycin
bear
similar
side
chain
c
atom
aglycon
henc
short
mithramycin
acid
becom
avail
compar
combinatori
biosynthesi
use
chemic
modif
mithramycin
olivomycin
two
carbohydr
chain
bear
acetyl
group
posit
olios
moieti
isobutyryl
group
posit
olivomycos
moieti
seri
analogu
compound
differ
set
function
group
synthes
order
elucid
influenc
acyl
substitu
carbohydr
chain
biolog
activ
two
analogu
c
synthes
select
alkalin
hydrolysi
group
olivomycin
c
respect
scheme
worth
note
hydrolysi
group
olivomycin
antibiot
olivomycin
b
isol
natur
olivomycin
complex
produc
ferment
streptoverticillum
cinnamoneum
strain
purif
silica
gel
column
chromatographi
semiprepar
hplc
compound
isol
yield
respect
compound
ident
previous
character
natur
olivomycin
c
b
respect
modif
antibiot
c
phenol
group
aromat
ring
compound
found
effect
antiprolif
activ
cancer
cell
line
alter
abil
inhibit
topoisomeras
transform
give
diazenyl
deriv
accompani
elimin
disaccharid
branch
aglycon
compound
lead
sharp
decreas
antiprolif
activ
compar
start
olivomycin
compound
acquir
consider
select
activ
human
immunodefici
virus
assay
human
tlymphocyt
cell
line
cem
evalu
antiprolif
activ
olivomycin
analogu
modifi
sidechain
h
keto
group
aglycon
cm
amid
leukaemia
cell
line
show
compound
effect
start
acid
less
activ
compound
deriv
antibiot
shorter
aglycon
side
chain
osa
amid
evalu
antiprolif
activ
human
chronic
myeloid
leukaemia
cell
line
human
colon
evalu
antiprolif
activ
olivomycin
analogu
cell
show
acyl
group
carbohydr
chain
antibiot
play
signific
role
activ
decreas
elimin
acyl
group
molecul
ic
mmol
l
compound
result
correl
data
abil
compound
inhibit
dnadepend
topoisomeras
absenc
antibiot
relax
supercoil
sc
dna
lead
disappear
inhibitori
activ
format
set
topoisom
inhibit
topoisomeras
detect
presenc
residu
amount
scdna
decreas
amount
rapidli
migrat
topoisom
decreas
inhibitori
activ
enzym
consist
decreas
antiprolif
activ
seri
compound
remov
group
trisaccharid
branch
lower
effect
remov
group
disaccharid
branch
similar
pattern
activ
observ
anoth
group
olivomycin
deriv
compound
display
low
antiprolif
activ
inact
topoisomeras
h
carboxymethoxim
olivomycin
n
amid
activ
assay
h
carboxymethoxim
olivomycin
n
tertbutyl
amid
h
carboxymethoxim
olivomycin
n
amid
even
effect
inhibitor
enzym
capabl
inhibit
scdna
relax
even
concentr
mmol
l
data
antiprolif
activ
analogu
antibiot
correl
activ
topoisomeras
exampl
analogu
olivomycin
osa
exhibit
weak
antiprolif
activ
display
inhibitori
activ
topoisomeras
similar
olivomycin
wherea
dmaeosa
possess
high
antiprolif
activ
weaker
inhibitor
enzym
recent
shown
highli
effect
analogu
act
dna
duplex
minor
groov
ligand
anoth
assay
disrupt
key
epigenet
dna
methyl
process
enzym
equal
basi
antibiot
compound
inhibit
format
dna
coval
bond
requir
methyl
nearli
equal
micromolar
concentr
olivomycin
complex
model
oligonucleotid
dna
duplex
studi
circular
dichroism
cd
fluoresc
titrat
ft
accord
hartre
fock
calcul
structur
dimer
mg
presenc
dmae
group
compound
lead
increas
bind
constant
k
mg
complex
dna
duplex
order
magnitud
compar
acid
osa
k
versu
mol
l
evalu
ft
howev
presenc
bulki
adamantyl
substitu
compound
result
decreas
bind
constant
dimer
mg
dna
duplex
order
magnitud
k
mol
l
elimin
one
acyl
substitu
also
lead
decreas
antiprolif
activ
compar
antibiot
due
probabl
decreas
affin
dna
molecular
dock
complex
dna
show
antibiot
bind
gcrich
region
minor
groov
dna
duplex
carbohydr
chain
olivomycin
interact
sugar
phosphat
backbon
dna
aglycon
interact
nucleic
acid
base
site
respons
interact
dna
addit
hydrogen
bond
nh
group
g
base
complex
antibiot
dna
identifi
structur
fragment
directli
involv
interact
dna
model
affin
antibiot
target
minor
groov
dna
duplex
determin
base
data
schemat
model
interact
olivomycin
dna
propos
scheme
two
semisynthet
olivomycin
deriv
modifi
aglycon
side
chain
chosen
base
evalu
antiprolif
activ
anim
assay
compound
effect
treatment
murin
leukaemia
start
antibiot
due
decreas
toxic
absenc
cumul
effect
compound
olivamid
also
effect
assay
compar
start
antibiot
detail
preclin
assay
transplant
syngen
tumour
confirm
efficaci
agent
base
compound
clinic
trial
studi
enabl
develop
method
select
chemic
modif
antibiot
olivomycin
result
synthesi
seri
semisynthet
deriv
antibiot
besid
structur
activ
relationship
analysi
perform
mani
compound
exhibit
high
antiprolif
activ
differ
tumour
cell
line
aspect
mechan
action
olivomycin
natur
semisynthet
analogu
consid
conclud
high
antitumour
activ
compound
relat
high
affin
dna
duplex
base
result
vitro
assay
compound
chosen
evalu
antitumour
activ
vivo
assay
preclin
evalu
antitumour
activ
toxic
laboratori
anim
semisynthet
olivomycin
analogu
olivamid
recommend
clinic
trial
anthracyclin
antibiot
import
chemotherapeut
agent
commonli
use
treatment
malign
tumour
daunorubicin
independ
discov
name
rubomycin
gaus
institut
new
antibiot
gina
appli
mainli
treatment
leukaemia
children
adult
doxorubicin
dox
use
combin
chemotherapi
breast
cancer
smallcel
lung
cancer
sarcoma
tumour
children
haemoblastosi
origin
method
onepot
prepar
semisynthet
doxorubicin
rubomycin
develop
gina
carminomycin
also
discov
gina
lower
cardiotox
anthracyclin
inhibit
growth
doxorubicinresist
tumour
structur
anthracyclin
antibiot
shown
fig
mechan
cytotox
activ
anthracyclin
antibiot
relat
mainli
inhibit
nucleic
acid
synthesi
via
intercal
nitrogen
base
pair
dna
damag
inhibit
dna
topoisomeras
advers
effect
anthracyclin
potenti
irrevers
cumul
doserel
cardiotox
appar
associ
freerad
damag
myocardi
cell
membran
chemic
modif
anthracyclin
antibiot
extens
studi
gina
long
period
time
recent
year
effort
focus
synthesi
new
semisynthet
analogu
drug
improv
anticanc
properti
daunorubicim
carminomycin
modifi
c
atom
b
c
bond
c
daunosamin
h
amino
group
e
see
fig
h
nalkyl
h
naminoacyl
deriv
exhibit
high
antitumour
activ
retain
amin
function
daunosamin
moieti
function
requir
primari
interact
antibiot
sugar
phosphat
backbon
dna
howev
drawback
reduct
alkyl
anthracyclin
aldehyd
presenc
nabh
cn
accompani
reduct
c
group
side
reaction
give
deriv
daunorubicin
carminomycin
respect
scheme
analogu
less
activ
relat
compound
contain
c
group
ketal
deriv
daunorubicin
carminomycin
use
avoid
side
reaction
see
scheme
reduct
alkyl
compound
presenc
nabh
cn
accomplish
use
lglyceraldehyd
aldos
monosaccharid
arabinos
disaccharid
melibios
form
follow
ketal
quantit
yield
antiprolif
activ
compound
leukaemia
cell
virtual
high
deriv
lower
carminomycin
activ
deriv
evalu
assay
order
magnitud
lower
start
anthracyclin
activ
doxorubicin
two
order
magnitud
lower
compound
emphas
deriv
equal
activ
wildtyp
human
breast
adenocarcinoma
cell
line
resist
pgpexpress
cell
line
antitumour
activ
compound
evalu
murin
leukaemia
cell
line
compar
favour
analogu
thu
increas
life
span
il
mice
bear
leukaemia
singl
administr
mg
kg
compound
observ
administr
analogu
dose
mg
kg
il
shown
anthracyclin
antibiot
known
inhibit
dna
topoisomeras
ii
micromolar
concentr
inhibit
dna
topoisomeras
concentr
new
deriv
higher
inhibitori
activ
topoisomeras
compar
compound
introduct
polyhydroxyl
substitu
h
amino
group
daunosamin
moieti
anthracyclin
antibiot
increas
inhibitori
activ
anthracyclin
topoisomeras
method
develop
prepar
new
watersolubl
depot
form
doxorubicin
conjug
highmolecularmass
polysaccharid
galactomannan
davanat
use
polysaccharid
latter
prepar
control
partial
hydrolysi
waterinsolubl
highmolecularmass
isol
seed
cyamopsi
tetragonoloba
guar
gum
molecular
mass
compound
determin
gel
chromatographi
sephadex
column
calibr
pullulan
kda
conjug
compound
former
activ
oxid
period
use
defici
amount
oxid
agent
equiv
respect
total
amount
sugar
residu
give
rise
schiff
base
aldehyd
group
oxid
polysaccharid
h
amino
group
antibiot
scheme
differ
structur
final
product
possibl
content
start
antibiot
conjug
mass
determin
content
chromophor
per
unit
mass
dri
powder
uv
spectroscopi
nm
order
increas
doxorubicin
content
conjug
davanat
antibiot
molecul
attach
polysaccharid
spacer
give
h
nllysyldoxorubicin
scheme
compound
contain
two
amino
group
doxorubicin
contain
one
amino
group
may
facilit
format
schiff
base
besid
known
seri
nacyl
conjug
daunorubicin
doxorubicin
amino
acid
possess
high
antitumour
activ
h
nllysyldoxorubicin
synthes
acyl
amino
group
doxorubicin
n
n
e
fmoc
llysin
osuest
follow
deprotect
fmocprotect
intermedi
morpholin
solut
schiff
base
result
conjug
either
linear
cyclic
structur
scheme
present
possibl
structur
one
oxid
subunit
activ
davanat
note
h
nllysyldoxorubicin
attach
conjug
either
aaminoor
eamino
group
h
nllysyldoxorubicin
shown
scheme
introduct
lysin
spacer
compound
allow
increas
antibiot
content
conjug
mass
retent
water
solubl
conjug
purifi
gel
chromatographi
sephadex
column
dialysi
deioniz
water
use
membran
molecular
weight
cutoff
mwco
w
kda
molecular
mass
conjug
evalu
gel
chromatographi
sephadex
column
calibr
pullulan
standard
kda
respect
antiprolif
activ
doxorubicin
conjug
test
three
tumour
cell
line
murin
melanoma
cell
line
breast
cancer
cell
line
colon
cancer
cell
line
ic
valu
conjug
take
account
percentag
antibiot
conjug
mg
ml
respect
antibiot
mg
ml
despit
fact
cytotox
conjug
order
magnitud
lower
data
report
doxorubicin
result
indic
conjug
activ
depot
form
doxorubicin
antiprolif
activ
h
nllysyldoxorubicin
davanat
conjug
ic
mg
ml
tumour
cell
line
much
lower
compar
cytotox
conjug
due
fact
imin
bond
h
nllysyldoxorubicin
davanat
conjug
stabl
conjug
note
h
nllysyldoxorubicin
releas
vitro
assay
therefor
biolog
model
would
provid
releas
appar
requir
evalu
therapeut
potenti
conjug
base
studi
method
develop
introduct
polyhydroxyl
substitu
differ
type
differ
length
anthracyclin
antibiot
use
synthes
seri
new
hydrophil
h
nalkyl
deriv
doxorubicin
includ
contain
monoand
disaccharid
residu
modif
found
enhanc
inhibitori
activ
anthracyclin
topoisomeras
retent
antitumour
activ
antibiot
new
deriv
unlik
doxorubicin
deriv
shown
suppress
tumour
cell
growth
insensit
doxorubicin
new
watersolubl
depot
form
doxorubicin
conjug
highmolecularmass
polysaccharid
galactomannan
davanat
prepar
depot
form
exhibit
antiprolif
activ
abovement
three
tumour
cell
line
antibiot
heliomycin
resistomycin
cd
broad
spectrum
biolog
activ
scheme
discov
gaus
institut
new
antibiot
first
antibiot
highli
effect
gramposit
gramneg
microorgan
includ
drugresist
strain
recent
heliomycin
found
exhibit
antifung
antivir
antihiv
activ
besid
compound
block
prolifer
tumour
cell
vitro
assay
soviet
union
heliomycin
produc
commerci
scale
use
gel
topic
treatment
skin
infect
heal
burn
wound
chemic
modif
heliomycin
poorli
known
henc
structur
activ
relationship
studi
requir
develop
method
synthesi
new
semisynthet
deriv
evalu
biolog
properti
main
goal
prepar
seri
deriv
improv
water
solubl
order
expand
practic
applic
method
develop
synthesi
aminomethyl
deriv
posit
compound
x
amin
moieti
nitrogencontain
heterocycl
typic
synthet
procedur
present
relat
compound
c
see
scheme
mannich
aminomethyl
compound
perform
use
amin
formaldehyd
dmf
see
scheme
b
altern
procedur
synthesi
deriv
base
use
preprepar
stabl
iminium
salt
see
scheme
condit
case
aminomethyl
compound
polyfunct
amin
amino
group
protect
boc
see
scheme
c
deprotect
acid
see
scheme
reaction
compound
n
ndimethylamino
methylen
ammonium
chlorid
afford
n
ndimethylamino
methyl
cd
hydrochlorid
tertbutylamino
methyl
cd
hydrochlorid
produc
treatment
compound
tertbutylmethylamin
presenc
formaldehyd
treatment
compound
presenc
formaldehyd
solut
give
cd
quantit
convert
correspond
amin
dihydrochlorid
upon
treatment
antiprolif
activ
ic
evalu
colorimetr
determin
cell
metabol
activ
mtt
assay
use
standard
procedur
eight
tumour
cell
line
includ
drugsensit
drugresist
cell
line
result
compound
inhibit
tumour
cell
prolifer
low
submicromolar
micromolar
concentr
rang
similar
doxorubicin
howev
compound
significantli
outperform
doxorubicin
term
drugresist
index
compound
block
growth
wildtyp
cell
line
follow
multidrugresist
cell
line
sublin
isogen
pglycoprotein
pgp
posit
multidrug
resist
sublin
gene
delet
develop
multidrug
resist
tumour
cell
line
crucial
factor
respons
decreas
activ
antitumour
drug
oppos
compound
deriv
c
show
high
level
induc
apoptosi
bladder
cancer
cell
line
model
introduct
moieti
enhanc
dnabind
affin
inhibitori
activ
dna
topoisomeras
henc
compound
promis
candid
preclin
trial
base
studi
method
develop
chemic
modif
heliomycin
seri
new
analogu
watersolubl
salt
aminocontain
deriv
synthes
shown
exhibit
high
antiprolif
activ
mani
tumour
cell
line
inhibitori
activ
variou
target
valu
studi
major
aminomethyl
deriv
heliomycin
activ
wildtyp
drugresist
cancer
cell
micromolar
submicromolar
concentr
develop
newgener
drug
challeng
problem
increas
risk
develop
drug
resist
microorgan
differ
approach
search
new
compound
develop
recent
year
particular
attent
given
semisynthet
deriv
base
avail
natur
antibiot
sinc
numer
exampl
success
applic
approach
semisynthet
deriv
base
macrocycl
glycopeptid
advantag
gold
standard
chemotherapeut
agent
vancomycin
distinguish
featur
new
repres
class
select
multidrugresist
pathogen
bacteria
higher
bioavail
new
semisynthet
vancomycin
analogu
telavancin
vibativ
manufactur
therav
astella
pharma
us
approv
use
unit
state
europ
two
semisynthet
deriv
glycopeptid
antibiot
complet
phase
clinic
trial
approv
unit
state
food
drug
administr
fda
chloroeremomycin
discov
eli
lilli
acquir
medicin
co
dalbavancin
discov
lepetit
acquir
pfizer
drawback
vancomycin
poor
accumul
within
tissu
use
treatment
exampl
pneumonia
pronounc
pseudoallerg
reaction
typic
glycopeptid
research
intern
cooper
show
promis
chemic
transform
antibiot
eremomycin
belong
group
glycopeptid
antibiot
eremomycin
highli
activ
domest
antibiot
suppress
growth
gramposit
organ
time
effect
vancomycin
inact
drugresist
strain
staphylococci
enterococci
origin
approach
method
develop
supervis
professor
mnpreobrazhenskaya
gaus
institut
new
antibiot
method
appli
prepar
deriv
antibiot
group
desir
properti
method
synthesi
glycopeptid
analogu
protect
intern
patent
promis
analogu
variou
n
h
deriv
carboxamid
eremomycin
synthes
deriv
compar
favour
efficaci
drugsensit
drugresist
strain
staphylococci
enterococci
relat
vancomycin
deriv
even
effect
number
assay
carboxamid
show
allergen
deriv
eg
adamantan
deriv
eremomycin
promis
protect
biolog
risk
found
activ
bacterium
bacillu
anthraci
includ
fluoroquinoloneresist
strain
high
activ
result
hydrophob
glycopeptid
deriv
attribut
dual
mechan
action
gramposit
bacteria
modif
aglycon
glycopeptid
antibiot
hydrophob
substitu
result
discoveri
new
class
polycycl
peptid
activ
larg
group
envelop
virus
hiv
hepat
c
viru
studi
mechan
antivir
activ
current
ongo
suggest
protein
kinas
one
possibl
target
agluco
analogu
antivir
activ
shown
correl
inhibit
serin
threonin
protein
kinas
comprehens
research
synthesi
character
heterodimer
conjug
base
differ
class
antibiot
initi
gaus
institut
new
antibiot
supervis
professor
mnpreobrazhenskaya
follow
hybrid
antibiot
synthes
glycopeptid
macrolid
glycopeptid
aminoglycosid
hybrid
compound
contain
benzoxaborol
chromophor
literatur
data
provid
evid
line
research
hold
promis
macrolid
modifi
carbamoyl
group
hh
posit
acquir
activ
drugresist
bacteri
cell
line
gener
conjug
contain
long
spacer
exhibit
higher
activ
relat
compound
shorter
spacer
investig
interact
differ
benzoxaborol
antibiot
made
signific
contribut
chemistri
antibiot
complex
structur
also
rel
poorli
studi
borol
compound
benzoxaborol
found
quit
stabl
differ
reaction
condit
particular
acyl
amid
reduct
alkyl
reactiv
agent
heat
virtual
accompani
oxaborol
ring
open
introduct
benzoxaborol
substitu
polyen
macrolid
amphotericin
b
amb
also
enhanc
biolog
activ
result
compound
possess
valuabl
properti
lower
cytotox
haemolyt
activ
compar
amb
combin
high
antifung
activ
effici
approach
design
antibiot
new
gener
demonstr
relat
antifung
polyen
macrolid
base
combin
genet
engin
techniqu
method
organ
synthesi
protect
intern
patent
chemic
modif
polyen
antibiot
obtain
via
genet
engin
nystatin
biosynthesi
norwegian
univers
gave
seri
agent
exhibit
lower
toxic
higher
activ
compar
amphotericin
b
anim
assay
depend
antifung
activ
structur
polyol
region
c
c
antibiot
reveal
first
time
preobrazhenskaya
et
al
pioneer
studi
develop
method
select
chemic
modif
uniqu
macrolacton
oligomycin
specif
f
f
atp
synthas
inhibitor
origin
antitumour
antibiot
olivomycin
aureol
acid
group
perform
case
exampl
chemic
modif
relat
compound
antibiot
absent
literatur
result
great
scientif
valu
investig
f
f
atp
synthas
inhibitor
consider
interest
enzym
involv
develop
resist
microorgan
chemic
transform
oligomycin
use
differ
reagent
studi
detail
alkalin
hydrolysi
reaction
perform
condit
select
reduct
doubl
bond
keto
group
cycliz
etc
found
replac
c
hydroxyl
group
activ
mesyl
group
prove
particularli
success
modif
signific
effect
biolog
activ
antibiot
provid
possibl
optim
pharmacolog
properti
transform
via
biosynthesi
describ
aureol
acid
group
antibiot
mithramycin
chromomycin
natur
antibiot
limit
use
treatment
malign
tumour
attract
increas
attent
research
differ
field
synthes
compound
test
antiprolif
activ
base
result
vitro
studi
seri
new
olivomycin
analogu
differ
type
compound
select
vivo
evalu
preclin
trial
laboratori
anim
evaluatrion
antitumour
activ
toxic
one
olivomycin
analogu
recommend
clinic
trial
system
approach
appli
seri
new
semisynthet
analogu
olivomycin
allow
detail
studi
molecular
mechan
antitumour
action
antibiot
particular
shown
olivomycin
analogu
act
dna
duplex
minor
groov
ligand
inhibit
topoisomeras
enzym
respons
disrupt
key
epigenet
dna
methyl
process
structur
fragment
olivomycin
critic
antitumour
activ
identifi
model
interact
antibiot
analogu
dna
duplex
propos
new
analogu
anthracyclin
antibiot
substitu
differ
type
differ
length
includ
contain
monoand
disaccharid
residu
prepar
evalu
effect
polyhydroxyl
moieti
doxorubicin
antitumour
activ
show
modif
lead
loss
activ
anthracyclin
enhanc
inhibitori
activ
topoisomeras
deriv
prove
particularli
valuabl
compound
oppos
relat
doxorubicin
deriv
inhibit
prolifer
doxorubicinsensit
doxorubicinresist
tumour
cell
line
new
watersolubl
depot
form
doxorubicin
highmolecularmass
polysaccharid
galactomannan
davanat
construct
shown
exhibit
antiprolif
activ
three
tumour
cell
line
seri
new
heliomycin
analogu
watersolubl
salt
amino
deriv
synthes
compound
shown
high
antiprolif
activ
mani
tumour
cell
line
inhibitori
activ
differ
target
valu
studi
major
aminomethyl
deriv
heliomycin
activ
wildtyp
drugresist
cancer
cell
micromolar
submicromolar
concentr
method
protect
patent
target
chemic
modif
antibiot
perform
order
prepar
new
potenti
drug
new
gener
use
effici
tool
investig
mechan
action
bacteri
tumour
cell
emphas
mani
potent
antibiot
indispens
tool
molecular
biolog
research
live
world
comprehens
studi
lead
design
synthesi
newgener
drug
would
effect
start
antibiot
theoret
interest
new
compound
high
biolog
activ
figur
compos
author
base
cite
public
refer
given
figur
caption
